COMPANY

Cocrystal Pharma Inc.

HQ: Bothell, WA source · cocrystalpharma.com ↗ · West Coast

Keywords: infectious disease influenza severe acute respiratory syndrome Middle East respiratory syndrome respiratory Influenza A Norovirus Chronic Hepatitis C Hepatitis C CDI-988 CC-42344 CDI-31244

Location: Bothell, WA · source · Sep 9, 2026

Profile checked Oct 10, 2026

$5.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Aug 3, 2026 Raise Private placement: $5M (total, as published), announced Aug 3, 2026. Source: SEC filing. source ↗
Mar 1, 2026 Trial start Phase 1/Phase 2: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus source ↗
Oct 27, 2025 Grant Government grant: $500,000 (total, as published), announced Oct 27, 2025. Source: company release on GlobeNewswire. source ↗
Nov 25, 2023 Trial start Phase 2: Influenza Viral Challenge Study of CC-42344 in Healthy Participants source ↗
Sep 27, 2023 Trial start Phase 1: CDI-988 Safety Study in Healthy Participants source ↗
Feb 11, 2022 Trial start Phase 1: CC-42344 Safety Study in Healthy Participants source ↗
Jun 26, 2018 Trial start Phase 2: Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) source ↗
2016-04 Trial start Phase 1: A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects source ↗

Upcoming milestones

Oct 1, 2026 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus · NCT07198139

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $5.0M. Last 2 years.

Aug 3, 2026 Private placement: $5M (total, as published), announced Aug 3, 2026. Source: SEC filing. source ↗
Oct 27, 2025 Government grant: $500,000 (total, as published), announced Oct 27, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT05977140	CDI-988 Safety Study in Healthy Participants	Phase 1	Completed	Sep 27, 2023	May 23, 2025 (actual)
NCT05202379	CC-42344 Safety Study in Healthy Participants	Phase 1	Completed	Feb 11, 2022	Mar 29, 2023 (actual)
NCT07198139	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus	Phase 1/Phase 2	Recruiting	Mar 1, 2026	Oct 1, 2026 (estimated)
NCT06160531	Influenza Viral Challenge Study of CC-42344 in Healthy Participants	Phase 2	Completed	Nov 25, 2023	May 3, 2024 (actual)
NCT03501550	Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)	Phase 2	Completed	Jun 26, 2018	Jan 8, 2019 (actual)
NCT02760758	A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects	Phase 1	Completed	2016-04	2017-03 (actual)